# Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.

> **NCT02189733** · PHASE1 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Caplacizumab

## Key facts

- **NCT ID:** NCT02189733
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-09
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02189733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02189733, "Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02189733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*